JP2016539172A - 癌標的化及び抗体作製のための抗ガングリオシド化合物 - Google Patents

癌標的化及び抗体作製のための抗ガングリオシド化合物 Download PDF

Info

Publication number
JP2016539172A
JP2016539172A JP2016536849A JP2016536849A JP2016539172A JP 2016539172 A JP2016539172 A JP 2016539172A JP 2016536849 A JP2016536849 A JP 2016536849A JP 2016536849 A JP2016536849 A JP 2016536849A JP 2016539172 A JP2016539172 A JP 2016539172A
Authority
JP
Japan
Prior art keywords
ganglioside
carbohydrate
cancer
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539172A5 (cg-RX-API-DMAC7.html
Inventor
エイチ ウリ サラゴヴィ
エイチ ウリ サラゴヴィ
ウェンヨン トン
ウェンヨン トン
Original Assignee
ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ
ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ, ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ filed Critical ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ
Publication of JP2016539172A publication Critical patent/JP2016539172A/ja
Publication of JP2016539172A5 publication Critical patent/JP2016539172A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016536849A 2013-12-06 2014-12-04 癌標的化及び抗体作製のための抗ガングリオシド化合物 Pending JP2016539172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912684P 2013-12-06 2013-12-06
US61/912,684 2013-12-06
PCT/CA2014/051165 WO2015081438A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Publications (2)

Publication Number Publication Date
JP2016539172A true JP2016539172A (ja) 2016-12-15
JP2016539172A5 JP2016539172A5 (cg-RX-API-DMAC7.html) 2017-03-09

Family

ID=53272688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536849A Pending JP2016539172A (ja) 2013-12-06 2014-12-04 癌標的化及び抗体作製のための抗ガングリオシド化合物

Country Status (7)

Country Link
US (1) US10363305B2 (cg-RX-API-DMAC7.html)
EP (2) EP3957327A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016539172A (cg-RX-API-DMAC7.html)
CN (1) CN106414472A (cg-RX-API-DMAC7.html)
CA (1) CA2968995A1 (cg-RX-API-DMAC7.html)
ES (1) ES2904533T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015081438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786586B2 (en) * 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
EP4225365A4 (en) * 2020-10-05 2024-11-13 AOA Dx COMPOSITIONS AND METHODS FOR CANCER DIAGNOSTIC

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003073397A (ja) * 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
JP2004518704A (ja) * 2000-11-29 2004-06-24 ブラッコ インターナショナル ビー．ヴイ． 結合能を有するシアリル・ルイスｘ類似物
JP2006347908A (ja) * 2005-06-14 2006-12-28 National Institute Of Advanced Industrial & Technology シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
WO2007026669A1 (ja) * 2005-09-02 2007-03-08 Shizuoka Prefectural Universities Corporation ウイルスレセプター糖鎖認識特異性の判別方法
JP2008031156A (ja) * 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435025D1 (de) * 1993-01-22 2007-10-25 Sloan Kettering Inst Cancer Gangliosid-KLH-Konjugatimpfstoffe mit QS-21 zur Verzögerung des Wiederauftretens eines Melanoms
AU2002354804A1 (en) * 2001-07-06 2003-01-21 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518704A (ja) * 2000-11-29 2004-06-24 ブラッコ インターナショナル ビー．ヴイ． 結合能を有するシアリル・ルイスｘ類似物
JP2003073397A (ja) * 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
JP2006347908A (ja) * 2005-06-14 2006-12-28 National Institute Of Advanced Industrial & Technology シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
WO2007026669A1 (ja) * 2005-09-02 2007-03-08 Shizuoka Prefectural Universities Corporation ウイルスレセプター糖鎖認識特異性の判別方法
JP2008031156A (ja) * 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARBOHYDRATE RESEARCH, vol. Vol.342(9), JPN6017033905, 2007, pages 1244 - 1248, ISSN: 0003708281 *
CARBOHYDRATE RESEARCH, vol. Vol.346(12), JPN6017033910, 2011, pages 1454 - 1466, ISSN: 0003708282 *
GLYCOCONJUGATE JOURNAL, vol. 14, JPN6017033912, 1997, pages 837 - 845, ISSN: 0003708283 *

Also Published As

Publication number Publication date
EP3077405B1 (en) 2021-11-03
EP3957327A1 (en) 2022-02-23
US10363305B2 (en) 2019-07-30
CN106414472A (zh) 2017-02-15
WO2015081438A1 (en) 2015-06-11
US20160303227A1 (en) 2016-10-20
CA2968995A1 (en) 2015-06-11
EP3077405A1 (en) 2016-10-12
EP3077405A4 (en) 2017-08-09
ES2904533T3 (es) 2022-04-05

Similar Documents

Publication Publication Date Title
AU2015305332B2 (en) Novel glycan conjugates and use thereof
US9493580B2 (en) Multivalent glycopeptide constructs and uses thereof
US8835613B2 (en) β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
CA1337403C (en) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
JP4713638B2 (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
KR102167438B1 (ko) 변형된 당지질들 및 이들을 제조하고 사용하는 방법들
US20240042000A1 (en) Carbohydrate structures and uses thereof
JP2016539172A (ja) 癌標的化及び抗体作製のための抗ガングリオシド化合物
HK40064500A (en) Anti-ganglioside compound for targeting cancer and generating antibodies
Rashidijahanabad Development of Carbohydrate Based Conjugate Vaccines Using Qβ Virus Like Particles with Anti-bacterial or Anti-cancer Properties
Tong et al. A synthetic GD2 carbohydrate tetramer vaccine elicits tumor-killing antibodies and is therapeutic against GD2+ tumors
JP2011102320A (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180723